Introduction:
In the current study, silver nanoparticles were prepared and synthesized in aqueous medium using the Scrophularia striata leaf extract as stabilizing and reducing agents. Also, we investigated the anti-chronic myeloid leukemia potentials of silver nanoparticles against BV173 (chronic myeloid leukemia in blast crisis), CML-T1 (chronic myeloid leukemia in lymphoid blast crisis), EM-2 (chronic myeloid leukemia in blast crisis; relapse after bone marrow transplantation), and JOSK-M (chronic myeloid leukemia in myelomonocytic) cell lines.

Material and methods:
Silver nanoparticles were characterized and analyzed using common nanotechnology techniques including UV-Vis and FT-IR Spectroscopy, Field Emission-Scanning Electron Microscopy (FE-SEM), Transmission Electron Microscopy (TEM), and Energy Dispersive X-ray Spectrometry (EDS). FT-IR analysis offered antioxidant compounds in the nanoparticles were the sources of reducing power, reducing silver ions to silver nanoparticles. FE-SEM and TEM images revealed a uniform spherical morphology in size of 19.72 nm for the green synthesized nanoparticles. DPPH test revealed similar antioxidant potentials for silver nanoparticles and butylated hydroxytoluene.

Results:
Silver nanoparticles had very low cell viability and anti-chronic myeloid leukemia properties dose-dependently against JOSK-M, EM-2, CML-T1, and BV173 cell lines without any cytotoxicity on the HUVEC cell line. The best result of cytotoxicity properties of silver nanoparticles against the above cell lines was observed in the case of CML-T1 cell line.

Conclusions:
After confirming in the in vivo and clinical trial studies, these nanoparticles can be administered to humans for the treatment of chronic myeloid leukemia.